Background-Hyperuricemia is common in chronic heart failure (CHF), and it is a strong independent marker of prognosis. Upregulated xanthine oxidase (XO) activity and impaired renal excretion have been shown to account for increased serum uric acid (UA) levels in CHF. Therapeutic interventions with allopurinol to reduce UA levels by XO inhibition have been shown to be beneficial. Discussions are ongoing whether UA itself is actively involved or it is a mere marker of upregulated XO activity within CHF pathophysiology. Therefore, the aim of this study was to test the effect of lowering UA by uricosuric treatment without XO inhibition on hemodynamic and metabolic characteristics of CHF. Impaired renal excretion of UA was taken into account. Methods and Results-Serum UA (SUA), urinary UA (uUA) excretion, and renal clearance test for UA (Cl UA ) were measured in 82 patients with CHF. SUA was significantly increased compared with controls of similar age (control, 5.45Ϯ0.70 mg/dL; New York Heart Association I, 6.48Ϯ1.70 mg/dL; New York Heart Association II, 7.34Ϯ1.94 mg/dL; New York Heart Association III, 7.61Ϯ2.11 mg/dL; PϽ0.01). Patients with CHF showed lower uUA excretion and Cl UA . On multivariate analysis, insulin, brain natriuretic peptide (PϽ0.01), and creatinine levels (Pϭ0.05) showed independent correlation with SUA. The treatment effect of the uricosuric agent benzbromarone was tested in 14 patients with CHF with hyperuricemia in a double-blind, placebo-controlled, randomized crossover study design. Benzbromarone significantly decreased SUA (PϽ0.01). Brain natriuretic peptide, left ventricular ejection fraction, and dimensions in echocardiographic assessment did not change after benzbromarone therapy. In contrast, fasting insulin (placebo, 18.8Ϯ8.9 U/mL; benzbromarone, 11.0Ϯ6.2 U/mL; PϽ0.05), homeostasis model assessment of insulin resistance index (placebo, 5.4Ϯ2.6; benzbromarone, 3.0Ϯ1.7; PϽ0.05), and tumor necrosis factor-␣ (placebo, 2.59Ϯ0.63 pg/mL; benzbromarone, 2.14Ϯ0.51 pg/mL; PϽ0.05) improved after benzbromarone, and the changes in tumor necrosis factor-␣ levels were correlated with reduction of SUA (PϽ0.05). Conclusions-These results show that UA lowering without XO inhibition may not have an effect on hemodynamic impairment in CHF pathophysiology. To the extent that these data are correct, this finding suggests that upregulated XO activity rather than UA itself is actively involved in hemodynamic impairment in CHF. Clinical Trial Registrationclinical trials.gov. Identifier: NCT00422318.
H yperuricemia is often observed in patients with chronic heart failure (CHF). Increased uric acid (UA) levels have been shown to relate to exercise capacity, inflammation markers, and diastolic dysfunction in such patients. [1] [2] [3] In addition, hyperuricemia in CHF predicts both symptomatic status (ie, morbidity) as well as impaired prognosis (ie, mortality), 4 suggesting that hyperuricemia significantly con-tributes to the pathophysiology of CHF. Upregulation of xanthine oxidase (XO) activity rather than decreased renal excretion has been identified as a major factor underlying Clinical Perspective on p 81 increased serum UA (SUA) levels in CHF. 5 The enzyme XO is a major source of reactive oxygen species accumulation in human physiology, and XO-derived reactive oxygen species may account for a range of detrimental processes within CHF pathophysiology such as endothelium dysfunction, inflammatory activation, metabolic impairment, and others. Accordingly, the concept of UA lowering by XO inhibition therapy has been tested in a range of studies showing beneficial effects in a number of surrogate markers in these patients, such as endothelial dysfunction and peripheral blood flow, 6 hospitalization, 7 B-type natriuretic peptide levels, 8 and metabolic imbalance. 9 However, the debate is ongoing whether high UA itself is actively involved or it is merely a marker of XO activity (and hence of increased radical accumulation). 10, 11 Previous studies using XO inhibition therapy to lower UA are not suitable to answer this differential question. Therefore, this study was designed to test in a different approach the effect of lowering UA by uricosuric treatment without XO inhibition on hemodynamic and metabolic characteristics of CHF. The uricosuric agent benzbromarone was used to increase UA renal excretion. Benzbromarone blocks tubular reabsorption of UA by acting on urate transporter-1. 12 In a cross-sectional observation, the relation of UA to clinical and metabolic parameters was analyzed. In particular, impaired renal excretion of UA was taken into account.
Methods

Study 1: Cross-Sectional Observational Study
In a cross-sectional observational study, we enrolled 82 consecutive patients with systolic CHF of ischemic and nonischemic cause. The diagnosis of CHF was based on clinical evidence of heart failure with shortness of breath, symptomatic exercise limitation, and peripheral edema with a disease history of at least 12 months and hospitalization in the past for worsening heart failure once or more. In all patients, evidence of left ventricular (LV) functional impairment (LV ejection fraction [LVEF] Ͻ50%) by radionuclide ventriculography and/or echocardiography was present. Patients were eligible for the study if they had the diagnosis of CHF as defined above, were 21 years or older, and gave written consent to the study. Patients had to be in clinically stable conditions and on individually adjusted treatment regimen, including ␤-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, spironolactone, diuretics, aspirin, and statins, that had been unchanged for at least 4 weeks before the study. Patients were excluded from the study if they had clinical signs of decompensated heart failure such as progressive edema, raised jugular venous pressure, ascites, or hepatomegaly. Patients were further excluded if they had a history of gout and/or were treated with antihyperuricemic agents, if they had diabetes mellitus and antidiabetic therapy, including insulin. Patients with CHF who had myocardial infarction or any surgery in the last year, renal injury (CrϾ2.0 mg/dL), hemodialysis therapy, or uncontrolled hypertension (blood pressure Ͼ160/105 mm Hg) were also excluded. Alcohol intake and diuretic use were quantitatively assessed. Alcohol intake was calculated as alcohol consumption of milligram alcohol per day according to patients' life history. Diuretics (furosemide) use was calculated as dose of day (milligrams per day). As a control group, we also enrolled 16 controls of similar age and sex with normal UA levels and normal cardiac function. The study had been approved by the Ethical Committee of Tottori University Hospital, and written informed consent was obtained from all subjects.
In all patients, blood sampling was performed from an antecubital vein under standardized conditions: after overnight fasting and after resting for at least 10 minutes in the supine position. We evaluated full blood count and routine chemical parameters, including SUA, brain natriuretic peptide (BNP), and immunoreactive insulin levels. We also determined serum tumor necrosis factor (TNF)-␣ levels by the high-sensitivity human TNF-␣ test (Quantikine HS, R&D Sys-tem, Minneapolis, MN) as described previously. 13 Impaired insulin sensitivity was assessed using homeostasis model assessment of insulin resistance index (HOMA-IR). 14 
Study 2: Placebo-Controlled Intervention Study
The treatment effect of the uricosuric agent benzbromarone was tested in a double-blind, placebo-controlled, randomized crossover study design. Enrollment criteria were similar to study 1. Patients were eligible for enrollment in the study if they had systolic CHF of ischemic or nonischemic cause as defined above and evidence of hyperuricemia (UA Ͼ7.0 mg/dL). Patients had to be in stable compensated conditions of CHF (New York Heart Association [NYHA] I-III) and on individually adjusted treatment regimen as described for study 1. Exclusion criteria were signs of decompensated heart failure, diabetes mellitus and antidiabetic therapy, or treatment with antihyperuricemic agents. Patients with CHF who had myocardial infarction or any surgery in the last 1 year, renal injury (Cr Ͼ2.0 mg/dL), or uncontrolled hypertension were also excluded.
After the baseline visit, 14 patients were randomly 1:1 allocated to either therapy with benzbromarone (50 mg/d) or matching placebo. After a treatment period of 8 weeks, each patient was switched to the respective opposite treatment option for another 8 weeks. There was a 4-week washout period between the 2 treatment periods. At baseline and after the each treatment phase, ECG, chest x-ray, echocardiography, and blood sampling were performed under fasting condition similar to study 1. The primary end point of the study was the change of BNP levels and change in echocardiographic parameters of left ventricle dimensions (end-systolic and end-diastolic diameters) and LVEF. Secondary end points were changes in parameters of glucose metabolism and lipid metabolism.
The study had been approved by the Ethical Committee of Tottori University Hospital, and written informed consent was obtained from all subjects. The study was registered with clinical trials.gov (Identifier: NCT 00422318).
Statistical Analyses
All data are expressed as the meanϮSEM if not stated otherwise. Comparisons between 2 groups were assessed for statistical significance by unpaired Student t test, and the values in multiple groups were assessed for significant differences by 1-way ANOVA with Fisher's post hoc test. Distribution for biochemical variables was evaluated for normal distribution using the Kolmogorov-Smirnov test, and logarithmic transformation was applied where necessary to allow a parametric statistical approach. Univariable and stepwise multivariate linear regression analyses (least-squares method) were used to determine the correlation between continuous variables and to detect independent contributors to the UA level in patients with CHF. Only variables with significant invariable correlation plus age and gender were included in multivariable analyses. The crossover trial was analyzed according to the recommendations of Hills and Armitage 15 for crossover trials. Repeated-measures ANOVA and paired t test were used when appropriate. A P value Ͻ0.05 was considered statistically significant.
Results
Study 1: Cross-Sectional Observation Study
Patients with CHF consisted of 22 with previous myocardial infarction, 33 with idiopathic dilated cardiomyopathy, 24
with valvular heart disease, and 3 with hypertensive heart disease. Twenty patients were in NYHA functional class I, 40 in class II, and 22 in class III. Sixty-nine patients (84%) were treated with furosemide, 69 patients (84%) received angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker therapy, 33 patients (40%) were on ␤-blockers, 16 received spironolactone (20%), 35 received aspirin (43%), The values are represented as meanϮSD and n (%). BMI indicates body mass index; IHD, ischemic heart disease. Figure 1A ). A direct association was observed between UA and plasma BNP levels (rϭ0.5, PϽ0.0001; Figure 2 ). Patients with CHF had lower uUA, Cl UA , and Cl UA /Cl Cr values compared with controls ( Figure  1C and 1D). Hyperuricemia (defined as UA Ն7.0 mg/dL) was observed in 46 of 82 patients with CHF (56.1%) but in none of the controls (PϽ0.0001). Prevalence of hyperuricemia increased with advancing CHF severity according to NYHA functional class ( Figure 1B) . No differences were observed for SUA levels or other clinical or biochemical parameters between the different etiologic subgroups of the patient population (data not shown).
In univariable analysis, SUA negatively correlated with Cl UA and Cl UA /Cl Cr and positively correlated with BNP, diuretics use, cardiothoracic ratio of chest x-ray, BUN, alcohol intake, creatinine, total cholesterol, immunoreactive insulin, and HOMA-IR (Table 3 ). In multivariate analysis, age and gender were included in addition to all variables that showed significant correlation in univariable analysis. Only BNP and insulin showed independent significant relations with SUA in this model (creatinine, Pϭ0.05; Table 4 ). 
Study 2: Placebo-Controlled Intervention Study
Fourteen patients with stable CHF had been included in the intervention study. The patients (60Ϯ5 years, men/women, 10/4) had ischemic (nϭ4) and nonischemic (nϭ10) etiology of CHF (NYHA I, 3; NYHA II, 8; NYHA III, 3) . Atrial fibrillation, hypertension, and hyperlipidemia were present in 4, 6, and 5 patients, respectively, and in 2 patients, abnormal results of an oral glucose tolerance test showed an formerly unknown abnormal glucose tolerance (HbA1c within normal limits). Medication furosemide (100%), angiotensin-converting enzyme inhibitor and/or angiotensin II receptor blockers (100%), ß-blocker (36%), spironolactone (29%), aspirin (43%), and statins (36%) remained stable throughout the study period, and no antidiabetic drug was started during the study.
The change of clinical and biochemical variable after the intervention is shown in Table 5 . SUA levels were significantly increases above normal values at baseline (10.2Ϯ1.1 mg/dL; range, 7.6 to 11.6 mg/dL). After treatment with benzbromarone, UA significantly decreased by 34% to 6.7Ϯ1.4 mg/dL (PϽ0.01), but no change was observed after placebo (PϾ0.2; Figure 3 ). Urinary UA excretion increased after benzbromarone treatment by 43% (PϽ0.05). Urinary UA excretion did not change after placebo (PϾ0.2; Figure 3 ).
The primary end point, BNP, did not change significantly after 8 weeks of benzbromarone therapy compared with placebo (Table 5 ). Furthermore, echocardiographic parame- Figure 4 ). Fasting glucose did not change significantly. A significant association was found of the decrease in UA levels with a decrease in HOMA-IR (rϭ0.57, PϽ0.05) and with decreased insulin levels (rϭ0.59, PϽ0.05; Figure 5 ). Serum TNF-␣ levels were significantly decreased after benzbromarone treatment compared with placebo (PϽ0.05), and changes in TNF-␣ levels significantly correlated with reduction of SUA levels (rϭ0.62, PϽ0.05; Figure 5 ). Other biochemical variables, including lipid profile, serum HDLcholesterol, LDL-cholesterol, total cholesterol, and triglycerides also did not change after 8 weeks on benzbromarone.
Clinical variables such as heart rate, blood pressure, and NYHA class did not change after benzbromarone therapy ( Table 5 ). No side effects of benzbromarone therapy have been reported during the trial, and in particular, no urolithiasis and significant increase in liver function tests occurred during treatment with benzbromarone.
Discussion
In this study, we confirmed hyperuricemia as a common characteristic in CHF. The degree and prevalence of hyperuricemia increase in parallel to CHF severity as assessed by NYHA class and BNP levels. The important and novel finding of this study is that the treatment with the uricosuric agent benzbromarone in patients with CHF had no effect to reduce BNP levels or on LV functional parameters. Furthermore, other measures of CHF disease severity have not been affected by benzbromarone therapy such as NYHA functional class, atrial natriuretic peptide (ANP), chest X-ray, HR, or BP. This finding suggests that reduction of increased UA levels by uricosuric therapy (ie, without inhibition of the XO pathway) has no effect on hemodynamic variables within CHF pathophysiology. This novel data from our study add valuable information to the ongoing discussion on the pathophysiologic role of hyperuricemia in CHF.
The significance of hyperuricemia as a predictor of symptomatic status and as a strong and independent prognostic marker in CHF has repeatedly been shown. 4, 16, 17 However, the debate is ongoing whether UA itself is actively involved in these processes or whether it functions merely as an indicator of XO activity, which has been shown to be upregulated in CHF. 5 In fact, the UA-generating enzyme XO is a major source of oxygen radical generation, and increased oxygen radical load has been accounted for a range of adverse effects in CHF pathophysiology. In accord with this concept, interventional studies using XO inhibitors have shown beneficial effects on a number of surrogate markers in these patients. 9 Gavin and Struthers 8 have shown that UA lowering with the XO inhibitor allopurinol resulted in reduced BNP levels in patients with systolic CHF. Cingolani et al 18 reported improved LVEF after therapy with oxypurinol, the active metabolite of allopurinol. From the OPT-CHF [Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure] trial, it has recently been reported that treatment with oxypurinol did not produce clinical improvements in unselected patients with CHF. A post hoc analysis, however, suggested that benefits occur in patients with increased SUA in a manner correlating with the degree of SUA reduction. 19 However, this therapeutic approach (ie, XO inhibition) is not suitable to distinguish between the effect of XO inhibition and of UA lowering itself. Therefore, in our study, we used the uricosuric drug benzbromarone that reduces UA through increased UA excretion without interfering with the XO enzymatic activity. The degree of UA reduction in this study (Ϫ34%) was in the range of previous studies using allopurinol therapy (Ϫ39%). 6 The lacking effect on hemodynamic and clinical measures of CHF, including ANP and BNP, LV function and diameter, and NYHA functional class suggests that UA lowering alone does not have a role in the regulation of these pathophysiologic factors. In fact, these observations further support the current pathophysiologic concept that indeed, increased XO activity rather than UA itself may be the underlying principle of the association of hyperuricemia with morbidity and mortality in CHF 11 (Figure 6 ). To our knowledge, this is the first study to evaluate the effect of benzbromarone on clinical and hemodynamic characteristics in CHF. George et al 20 have previously shown that treatment with probenecid, another uricosuric drug, did not improve endothelial function, whereas allopurinol showed a dose-dependent effect on endothelial function in this study. Furthermore, in diabetic patients, intervention with the UAdegrading enzyme uricase did not have an effect on limb blood flow despite significant decrease of UA levels. 21 These results are in full accord with our findings and strengthen the conclusion that XO inhibition, but not UA, itself is the active factor to interfere with hemodynamic regulation in CHF.
A secondary finding is the association between hyperuricemia and impaired insulin sensitivity in CHF. An association between UA and insulin resistance has repeatedly been shown in non-CHF conditions, [22] [23] [24] and has been confirmed in patients with CHF. 25 Moreover, the observed effect of UA lowering to improve insulin sensitivity suggests a metabolic interaction between UA and insulin-mediated glucose utilization. Impaired insulin sensitivity has been shown to be an intrinsic feature of CHF pathophysiology contributing to symptomatic status and to prognosis of patients. 26, 27 The effect of UA-lowering therapy on insulin sensitivity without affecting hemodynamic measures in CHF is an intriguing observation that further adds to the increasingly complex picture of metabolic imbalance in CHF.
In addition to overproduction of UA, impaired renal excretion is, of course, a further major mechanism of hyperuricemia. In fact, impaired renal function is common in CHF, and accordingly, an association between hyperuricemia and impaired renal function is commonly observed in patients with CHF. In accord, in our study, impaired renal UA excretion was associated with SUA levels, and treatment with benzbromarone increased UA excretion, thus reducing SUA level. However, undersecretion may be of secondary importance compared with overproduction to account for increased UA levels in CHF. In a prospective series of studies on Figure 6 . View of the XO metabolic pathway. Upregulated XO activity 5 accounts for hyperuricemia in CHF with stoichiometric cosynthesis of reactive oxygen species. Accordingly, XO inhibition rather than uricosuric therapy by preventing reactive oxygen species accumulation may account for the beneficial effects as observed in previous trials. 9 patients with CHF, we have shown that hyperuricemia relates to a range of clinical characteristics and to prognosis independent of renal function and of diuretic use. 1, 4, 25, 28 Interventional studies with allopurinol provided convincing evidence that UA reduction through inhibition of upregulated XO activity yield beneficial effects on multiple clinical and biochemical markers in CHF. Interestingly, these effects were observed in hyperuricemic patient populations, whereas normouricemic patients did not respond to a similar degree to XO inhibition. 29 Therefore, hyperuricemia may indeed be viewed as a clear and easy to measure marker of upregulated XO activity in CHF, regardless of renal impairment, which may doubtlessly contribute to UA accumulation in these patients as well.
Some limitations of the study should be discussed. First, in our study, we included consecutively patients with CHF due to both ischemic and nonischemic cause. Therefore, no conclusion can be drawn for etiologic subgroups of patients with CHF. In our study, patients with ischemic and nonischemic cause were comparable with regard to CHF severity and clinical and biochemical characteristics, allowing for a combined analysis. Furthermore, relatively few patients in our study were taking ß-blockers and it cannot be excluded that a more complete adherence to current treatment recommendations may have an effect on metabolic balance. The discussion on the effect of ß 1 -selective ß blockers on insulin sensitivity is ongoing and neutral or even positive effect of novel ß blockers such as nebivolol on insulin sensitivity have been reported. 30 The standard dose of benzbromarone for treatment of hyperuricemia in white patients is 100 mg/d; however, in Japan, a dose of 50 mg/d is typical and believed to be equivalent. The achieved UA lowering (Ϫ34%) is suggestive this indeed being the case. Finally, the mechanism of the improvement of insulin resistance by benzbromarone is not clear, and the evaluation of underlying biochemical pathways was not in the scope of this study. We observed decreasing TNF-␣ levels after benzbromarone therapy, and the degree of TNF-␣ reduction correlated with the change in UA. TNF-␣ is known to impair insulin sensitivity, 31 and it could be speculated that the reduction of TNF-␣ after benzbromarone may contribute to the metabolic effect on improved insulin sensitivity. We cannot exclude from this study that benzbromarone itself may have a direct effect on insulin sensitivity independently of the UA-lowering effect. There are, however, no previous reports to suggest a direct effect of benzbromarone on insulin sensitivity, suggesting that it is indeed the UA-lowering effect of benzbromarone that underlies the change in insulin sensitivity.
In conclusion, our results show that the UA-lowering therapy without XO inhibition does not have an effect on hemodynamic measures in patients with CHF. This neutral finding in accord with previous positive studies using the XO inhibition approach supports the suggestion that upregulated XO activity rather than UA itself may be the underlying principle of the observed association of hyperuricemia with CHF severity and prognosis. Although this finding advances our understanding of the pathophysiologic involvement of the XO metabolic pathway, it does not diminish the repeatedly observed effect of hyperuricemia as a powerful and indepen-dent marker of symptomatic status and of prognosis in CHF. The observed interaction of uricosuric treatment and improved insulin sensitivity is an intriguing observation that needs further investigation. Metabolic imbalance is emerging as an important feature within CHF pathophysiology contributing to morbidity and mortality of patients.
